We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Elevated Blood Sugar a Cardiovascular Disease Risk Not Linked to Cholesterol Levels

By LabMedica International staff writers
Posted on 21 Sep 2014
Individuals with prediabetes and diabetes are at high risk for cardiovascular events such as myocardial infarction that can be predicted by elevated levels of troponin T.

The protein troponin T binds to tropomyosin and helps position it on actin, and with the rest of the troponin complex modulates contraction of striated muscle. More...
In patients with stable coronary artery disease, troponin T concentrations have been found to be significantly associated with the incidence of cardiovascular death and heart failure.

In a recent study, investigators at Johns Hopkins University (Baltimore, MD, USA) reported that individuals with pre-diabetes or diabetes who displayed elevated levels of troponin T were approximately six times more likely to experience a cardiovascular incident than were those with normal blood sugar levels.

These findings were obtained by using a highly sensitive troponin T assay to determine levels of the protein in blood samples from more than 9,000 participants in the Atherosclerosis Risk in Communities Study (ARIC) at two time points. At the first measurement those with diabetes were two and a half times more likely to have elevated troponin levels than those without. At follow-up 14 years later, diabetics with elevated troponin were seen to be six times more likely to develop heart failure and four times more likely to have a heart attack.

Due to the link between cardiovascular disease and diabetes, patients with newly diagnosed diabetes are typically prescribed a cholesterol-lowering statin. "However, this study suggests that there may be people with diabetes whose heart risk may have nothing to do with cholesterol," said first author Dr. Elizabeth Selvin, associate professor of epidemiology at Johns Hopkins University. "Statin treatment may not be sufficient to prevent damage to the heart in people with diabetes. Even though there may be no symptoms yet, our research suggests there is microvascular damage being done to the heart which is leading to heart failure and even death. It puts what we know about heart damage in diabetes on its head. It looks like diabetes may be slowly killing heart muscle in ways we had not thought of before."

The study was published in the August 2014 online edition of the journal Circulation.

Related Links:
Johns Hopkins University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.